Emerald Mutual Fund Advisers Trust’s Akebia Therapeutics AKBA Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-188,299	Closed	-$2.43M	–	268
2015 Q4	$2.43M	Sell	188,299 -68,151	-27%	-$695K	0.13%	156
2015 Q3	$2.48M	Sell	256,450 -50,000	-16%	-$459K	0.16%	144
2015 Q2	$3.15M	Buy	306,450 +49,360	+19%	+$421K	0.24%	113
2015 Q1	$2.12M	Buy	+257,090	New	+$2.74M	0.17%	126

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's AKBA Position: Q1 2016 in Review

Emerald Mutual Fund Advisers Trust sold out of Akebia Therapeutics (AKBA) in Q1 2016, closing a stake of 188,299 shares — an estimated $2.43M sold.

Emerald Mutual Fund Advisers Trust first reported a position in AKBA in Q1 2015 and held it in 4 quarters. The position peaked at $3.15M in Q2 2015. 91 funds tracked by Wall St. Rank hold AKBA as of Q1 2016.

Emerald Mutual Fund Advisers Trust reported no remaining Akebia Therapeutics position as of Q1 2016 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 188,299 Akebia Therapeutics shares in Q1 2016, an estimated $2.43M.
Emerald Mutual Fund Advisers Trust first reported a position in Akebia Therapeutics in Q1 2015 and held it in 4 quarters.
Emerald Mutual Fund Advisers Trust's Akebia Therapeutics position peaked at $3.15M in Q2 2015.
91 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2016.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2016, filed 28 Apr 2016.